Ionis Pharmaceuticals, Inc. (IONS) Downgraded to Peer Perform by Wolfe Research

Market Context

Ionis Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $54.65 with a market capitalization of $12.6B. The stock has gained 31.1% over the past 52 weeks.

Analyst downgrades can weigh on a stock in the short term as institutional investors who follow Wolfe Research's research adjust their positions. However, downgrades also sometimes create buying opportunities if the market overreacts to the rating change. The reasoning behind the downgrade matters more than the rating itself.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Ionis Pharmaceuticals, Inc.

Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 16, 2026	Wolfe Research	Peer Perform	N/A
Jul 13, 2026	RBC Capital	Outperform	N/A
Jul 10, 2026	HC Wainwright & Co.	Buy	N/A
Jul 10, 2026	Barclays	Overweight	N/A
Jul 10, 2026	Morgan Stanley	Overweight	N/A

Related Tools: Analyst Ratings Dashboard | View IONS Stock Page